Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
R3 Vascular
AddedFeb 15, 2024
UpdatedJun 18, 2026
R3 Vascular

R3 Vascular

Series A

R3 Vascular: Innovating bioresorbable scaffold tech for effective peripheral arterial disease treatment.

HQ
Mountain View, CA, US
Founded
2019
Overview
Compare
Fundraising
Employees
Website

Founded with the mission to revolutionize the treatment of peripheral arterial disease (PAD), R3 Vascular specializes in developing bioresorbable scaffold technology. Their core product, the Magnitude BRS device, features a sirolimus coating and is noted for its exceptional thinness, with a strut thickness of just 98 microns. This innovative scaffold balances strength and flexibility, aiming to improve patient outcomes in the PAD market.

R3 Vascular's proprietary polymer and manufacturing processes set them apart in the medical device industry. The company has garnered attention for its cutting-edge technology and has attracted notable investors and experts in the field. Their achievements include successful clinical trials demonstrating the efficacy and safety of their scaffolds. Overall, R3 Vascular is making significant strides in enhancing the treatment landscape for PAD, impacting patient care and advancing medical technology.

R3 Vascular - Similar Companies

Traverse Vascular logo

Traverse Vascular

Cagent Vascular logo

Cagent Vascular

cagentvascular.com

Efemoral Medical logo

Efemoral Medical

VenoStent logo

VenoStent

venostent.com

Rist Neurovascular logo

Rist Neurovascular

ristneuro.com

Cross Vascular logo

Cross Vascular

Vascular Imaging logo

Vascular Imaging

Euphrates Vascular logo

Euphrates Vascular

Evident Vascular logo

Evident Vascular

Access Vascular logo

Access Vascular

Micro Medical Solutions logo

Micro Medical Solutions

Voyager Biomedical logo

Voyager Biomedical

TheraVasc logo

TheraVasc

PolyVascular logo

PolyVascular

polyvascular.com

Pulsar Vascular logo

Pulsar Vascular

R3 Vascular - Quick Facts

Who are R3 Vascular's competitors?

Companies similar to R3 Vascular include Traverse Vascular, Cagent Vascular, Efemoral Medical and VenoStent.

When was R3 Vascular founded?

R3 Vascular was founded in 2019.

Where is R3 Vascular's headquarters located?

R3 Vascular's headquarters is located in Mountain View, CA, US.

When was R3 Vascular's last funding round?

R3 Vascular's most recent funding round was for $17.8M (USD) in October 2020.

How much has R3 Vascular raised to-date?

As of Oct 8, 2020, R3 Vascular has raised a total of $17.8M (USD).

How many employees does R3 Vascular have?

R3 Vascular has 5 employees as of Feb 5, 2024.

R3 Vascular - Classification

Industry
  • Hardware
Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Americas
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Medical Devices
Tags
  • Healthtech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
SIC
  • 5000Wholesale Trade-durable Goods
  • 5040Professional And Commercial Equipment And Supplies
  • 5047Medical, Dental, And Hospital Equipment And Supplies
Show 7 more industry codes
NAICS
  • 330000Manufacturing
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 3900Miscellaneous Manufacturing Industries
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified